Loop Dx is a technology company.
Loop Dx has raised $30K across 1 funding round.
Loop Dx has raised $30K in total across 1 funding round.
Loop Dx has raised $30K in total across 1 funding round.
Loop Dx's investors include Health Wildcatters.
Loop Dx (Loop Diagnostics S.L.) is a Barcelona-based healthtech startup founded in 2018 that develops SeptiLoop, a rapid point-of-care diagnostic platform for early sepsis detection using immune activity biomarkers.[1][2][3] It targets bloodstream infections and sepsis management in critical care settings, serving hospitals and clinicians to enable timely treatment decisions that address a leading global cause of death—11 million annually, or 20% of all deaths—where delays reduce survival rates hourly.[2] The company solves the problem of slow traditional diagnostics (6 hours to 2 days) with a solution 10 times faster (results in 1 hour) and 3 times more effective, validated in over 500 patients across 5 international hospitals.[1][2]
With 8 employees, Loop Dx has raised around €3M (including €700K noted in one source and €3M in March 2023 from investors like Capital Cell, Cardiolink Group, and NextGenerationEU), achieving a valuation of €7.7M while advancing toward industrialization and holding UKCA certification.[1][2][3]
Loop Dx emerged in 2018 from Barcelona's biotech ecosystem, founded by Enrique Hernández Jiménez (immunologist with PhD in Biomedicine, HEALTH Barcelona Fellow, experience at Moebio and idiPAZ), Joan Vieyra Galí (product developer and regulatory expert with research and academic background), and Eduard Guerrero Aiguabella (COO and CFO).[3] The idea stemmed from the urgent need for rapid sepsis diagnosis, as existing methods fail to provide binary results quickly amid rising global mortality.[2]
Early traction included validation with 500+ suspected sepsis patients in hospitals like Bellvitge, Parc Taulí, Princesa, Revini, and Cochin (Barcelona, Madrid, Paris, Dnipro), accelerator participation (Stage2 2023 cohort, Health Wildcatters), and securing medical licenses like UKCA.[2][3] This built momentum toward pilots and funding rounds totaling €3M by 2023.[1]
Loop Dx rides the deeptech wave in diagnostics, fueled by POCT, digital health, and biotech convergence amid rising sepsis burdens from antimicrobial resistance and aging populations.[1][5] Timing aligns with post-pandemic emphasis on rapid critical care tools, Industry 4.0 automation, and EU funding like NextGenerationEU, positioning Spain's healthtech hub (Barcelona) as a leader.[1][2]
Market forces favor it: WHO-highlighted sepsis crisis demands faster tools to cut mortality and antibiotic overuse; Loop Dx influences ecosystems via collaborations (e.g., ICREA Centre UPC) and accelerators, accelerating adoption in global hospitals.[1][2][3]
Loop Dx is primed for expansion with ongoing pilots, open funding rounds, and manufacturing scale-up, potentially capturing sepsis diagnostics market share through EU-wide rollouts and further validations.[2] Trends like AI-enhanced omics and decentralized care will amplify its edge, evolving its role from innovator to standard in critical care. As sepsis claims millions yearly, Loop Dx's biomarker breakthrough could transform outcomes, tying back to its mission of pioneering rapid solutions where delays cost lives.[1][2]
Loop Dx has raised $30K across 1 funding round. Most recently, it raised $30K Seed in September 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2020 | $30K Seed | Health Wildcatters |